Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases.

Autor: Yadav D; Department of Life Science, Yeungnam University, Gyeongsan 38541, South Korea., Wairagu PM; Department of Biochemistry and Biotechnology, The Technical University of Kenya, Nairobi, Kenya., Kwak M; Department of Chemistry, Pukyong National University, Busan 48513, Korea., Jin JO; Department of Microbiology, University of Ulsan College of Medicine, Seoul 05505, Korea.
Jazyk: angličtina
Zdroj: Current drug metabolism [Curr Drug Metab] 2022; Vol. 23 (11), pp. 882-896.
DOI: 10.2174/1389200223666220803103039
Abstrakt: The lung is exposed to various pollutants and is the primary site for the onset of various diseases, including infections, allergies, and cancers. One possible treatment approach for such pulmonary diseases involves direct administration of therapeutics to the lung so as to maintain the topical concentration of the drug. Particles with nanoscale diameters tend to reach the pulmonary region. Nanoparticles (NPs) have garnered significant interest for applications in biomedical and pharmaceutical industries because of their unique physicochemical properties and biological activities. In this article, we describe the biological and pharmacological activities of NPs as well as summarize their potential in the formulation of drugs employed to treat pulmonary diseases. Recent advances in the use of NPs in inhalation chemotherapy for the treatment of lung diseases have also been highlighted.
(Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze: MEDLINE